Kenvue Inc. $KVUE Shares Bought by Eubel Brady & Suttman Asset Management Inc.

Eubel Brady & Suttman Asset Management Inc. raised its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 1.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 982,182 shares of the company’s stock after buying an additional 12,540 shares during the quarter. Kenvue comprises about 2.6% of Eubel Brady & Suttman Asset Management Inc.’s portfolio, making the stock its 16th biggest holding. Eubel Brady & Suttman Asset Management Inc.’s holdings in Kenvue were worth $20,557,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Pittenger & Anderson Inc. purchased a new stake in shares of Kenvue in the first quarter valued at about $30,000. TruNorth Capital Management LLC purchased a new stake in shares of Kenvue in the 1st quarter valued at $36,000. Truvestments Capital LLC purchased a new position in shares of Kenvue in the first quarter valued at approximately $37,000. Trust Co. of Vermont boosted its stake in shares of Kenvue by 266.8% in the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after purchasing an additional 1,150 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd boosted its stake in shares of Kenvue by 378.5% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after purchasing an additional 1,287 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on KVUE. Citigroup reduced their target price on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, October 9th. Redburn Partners set a $22.00 target price on shares of Kenvue in a research report on Friday, September 26th. Royal Bank Of Canada lowered their target price on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a research report on Friday, August 8th. Evercore ISI set a $18.00 target price on shares of Kenvue in a research report on Tuesday. Finally, Bank of America lowered their price objective on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating on the stock in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $20.90.

Kenvue Price Performance

Shares of NYSE KVUE opened at $14.49 on Wednesday. The firm has a market capitalization of $27.80 billion, a P/E ratio of 19.57, a PEG ratio of 2.18 and a beta of 0.72. Kenvue Inc. has a one year low of $14.05 and a one year high of $25.17. The company’s fifty day moving average is $17.64 and its two-hundred day moving average is $20.69. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.28 by $0.01. The company had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business’s revenue was down 4.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.